ORTHOSON completes £8.9m expanded Series A to accelerate back pain treatment’s progress to clinic
Big Pi Ventures & Yonghua Capital are new international investors in expanded
Oxford, UK, April 3 2022 – OrthoSon, which is developing novel motion-restoring
minimally invasive treatments for low back pain, is pleased to announce completion of
a £8.9m Series A fund round to help prepare its product for Phase I trials in the US. New
international investors in this expanded round include the Greek technology venture
capital firm Big Pi Ventures and the Chinese investment company Yonghua Capital.
Plans for this investment include completion of preclinical safety studies, plus regulatory
activity to prepare for US clinical trials expected to take place from 2025. This will be
followed by European and international clinical trials supporting global launch.
With the completion of this Series A fundraising, OrthoSon’s Board will be strengthened
as Aristos Doxiadis, Partner at Big Pi Ventures, and Mr. Wang Chong, Venture Partner
at Yonghua Capital, join as Director and Observer respectively. Existing investors also
participated in the financing.